

Special Issue

Epigenetics in Cancer and the Therapeutic Potential of Epi-Drugs

Message from the Guest Editors

Recent progresses in the field of epigenetics have clearly indicated that cancer cells not only display genetic mutations, but also epigenetic abnormalities, accounting for tumour development and progression. Therefore, global changes in the epigenetic topography could be considered a hallmark of cancer, and the modulation of epigenetic modifications could represent a strategy to selectively target tumour cells. It is not by chance that epigenetic compounds such as histone deacetylase (HDAC) inhibitors or DNA demethylating agents have been developed and used as antitumor drugs either in vitro or in vivo; some of these compounds have already entered clinical trials and showed a certain efficacy. The aim of this Special Issue is to focus on the molecular mechanisms of epigenetic regulation in cancer and to describe possible therapeutic approaches based on the use of epigenetic compounds. In addition, the Special Issue aims to provide the molecular characterization of the action mechanisms induced by epigenetic compounds, including HDAC inhibitors, demethylating agents or other drugs modulating the histone code or acting on nucleosome positioning.

Guest Editors

Dr. Sonia Emanuele

Dr. Antonietta Notaro

Dr. Adriana Celesia

Deadline for manuscript submissions

closed (30 April 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/117899

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).